Shots: The FIREFISH Part 2 study involves assessing risdiplam in 41 infants aged 1-7mos. with Type 1 SMA treated for 24mos., followed by an open-label extension The study met its 1EPs with 29% of infants sitting without support for 5sec by 12mos. as assessed by the Gross Motor Scale of BSID-III, 43.9% infants were able […]Read More
